Skin Conditions & Dermatology Clinical Trials Update: Week 25, 2026

Published June 19, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

This Phase 3 trial from Eli Lilly and Company explored the combination of two medications, ixekizumab and tirzepatide, in adults who have moderate-to-severe plaque psoriasis along with obesity or being overweight. The study included 281 participants across the United States and Puerto Rico. If successful, this treatment could help improve skin symptoms while also supporting weight reduction, addressing two common health concerns together.

Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

AbbVie's Phase 3 study tested the oral medication upadacitinib for adolescents and adults suffering from moderate to severe atopic dermatitis, also known as eczema. With over 900 participants worldwide, the trial has completed and results are available. This medication may provide a new systemic treatment option that can ease symptoms and improve daily life for people managing this chronic skin condition.

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

This ongoing Phase 3 trial by Incyte Corporation focuses on ruxolitinib cream for children and adolescents aged 6 to under 18 years who have moderate atopic dermatitis. The study is active but no longer recruiting, with sites in several countries including the United States. If effective, this topical treatment could offer young patients relief from symptoms and improve their quality of life without systemic side effects.

Skin Change Actions by Nursing

Researchers at the University of California, Los Angeles are conducting a Phase 2 trial involving a device called the SEM Scanner to detect early skin changes in nursing home residents. Early detection aims to prevent pressure injuries, which can be painful and lead to other complications. The study is actively recruiting over 4700 participants across multiple U.S. locations, potentially offering a way to protect vulnerable populations from common skin damage.

Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma

This Phase 2 trial at Memorial Sloan Kettering Cancer Center tested a new jet-injection method to deliver photodynamic therapy to patients with basal cell carcinoma, a common form of skin cancer. The study, completed in the United States with 16 participants, seeks to provide a less invasive treatment option that may reduce side effects compared to traditional surgery.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.